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Background. Array Comparative Genomic Hybridization (a-CGH) is a powerful molecular cytogenetic tool to detect genomic
imbalances and study disease mechanism and pathogenesis. We report our experience with the clinical implementation of this
high resolution human genome analysis, referred to as Chromosomal Microarray Analysis (CMA). Methods and Findings. CMA
was performed clinically on 2513 postnatal samples from patients referred with a variety of clinical phenotypes. The initial 775
samples were studied using CMA array version 4 and the remaining 1738 samples were analyzed with CMA version 5
containing expanded genomic coverage. Overall, CMA identified clinically relevant genomic imbalances in 8.5% of patients:
7.6% using V4 and 8.9% using V5. Among 117 cases referred for additional investigation of a known cytogenetically detectable
rearrangement, CMA identified the majority (92.5%) of the genomic imbalances. Importantly, abnormal CMA findings were
observed in 5.2% of patients (98/1872) with normal karyotypes/FISH results, and V5, with expanded genomic coverage,
enabled a higher detection rate in this category than V4. For cases without cytogenetic results available, 8.0% (42/524)
abnormal CMA results were detected; again, V5 demonstrated an increased ability to detect abnormality. Improved diagnostic
potential of CMA is illustrated by 90 cases identified with 51 cryptic microdeletions and 39 predicted apparent reciprocal
microduplications in 13 specific chromosomal regions associated with 11 known genomic disorders. In addition, CMA
identified copy number variations (CNVs) of uncertain significance in 262 probands; however, parental studies usually
facilitated clinical interpretation. Of these, 217 were interpreted as familial variants and 11 were determined to be de novo; the
remaining 34 await parental studies to resolve the clinical significance. Conclusions. This large set of clinical results
demonstrates the significantly improved sensitivity of CMA for the detection of clinically relevant genomic imbalances and
highlights the need for comprehensive genetic counseling to facilitate accurate clinical correlation and interpretation.
Citation: Lu X, Shaw CA, Patel A, Li J, Cooper ML, et al (2007) Clinical Implementation of Chromosomal Microarray Analysis: Summary of 2513
Postnatal Cases. PLoS ONE 2(3): e327. doi:10.1371/journal.pone.0000327
INTRODUCTION
Genomic imbalances are a major cause of congenital and develop-
mental abnormalities including dysmorphic features, mental
retardation and developmental delay, and multiple congenital
anomalies. Using routine cytogenetics techniques, chromosomal
imbalances such as aneuploidies and segmental aneusomies must
be larger than 3–5 Mb in size to be detected by GTG-banding at
450–600 band resolution [1]. In the past two decades, traditional
banding has been combined with targeted molecular technologies
to improve the resolution at which one can detect genomic
changes. Fluorescence In Situ Hybridization (FISH) [2], Com-
parative Genomic Hybridization (CGH) [3] and Multiplex-FISH
[4] or Spectral Karyotyping (SKY) [5] have been used to detect
additional complex or submicroscopic abnormalities; however,
such technologies are not suitable for whole genome scans in
routine clinical testing because they either lack the necessary
resolution or are too time consuming, labor intensive, and/or
costly [6–8]. Array CGH technology has higher resolution and
excellent throughput when compared with conventional and
molecular cytogenetics [9–11]. In array CGH, genomic DNA
from the patient and reference are labeled with different
fluorescent dyes and co-hybridized to the array matrix containing
clone DNA. The content of an array may include specific targeted
regions of the genome or the entire genome arrayed on a single
glass slide. Similar to conventional CGH, genome imbalances are
quantified by analyzing the ratio of the two fluorescent hybridizing
signals. The resolution of array CGH is determined by the size and
number of the clones placed on the array to interrogate genome
copy number changes. Using 1-Mb average coverage (3500 clones)
BAC/PAC array analysis was shown to detect cryptic chromo-
somal imbalances in patients with idiopathic mental retardation
and multiple congenital anomalies [12–14]. A tiling path BAC
array (32K clones) has been developed and implemented in the
clinical research field to identify novel genes associated with
disease [15]. Chromosomal specific arrays, such as those for distal
chromosomes 1p, proximal 17p and chromosome 22, have been
utilized to identify subtle deletions and map specific rearrange-
ment breakpoints [16–18]. Using a combination of a 1 Mb
interval array and a specific chromosome 8 array, Visser and
colleagues were able to identify the critical genomic region and
disease gene responsible for CHARGE syndrome [19]. Exon array
CGH has also been reported as a method to measure copy-
number changes of individual exons in selected genes [20],
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ability to discriminate multi-copy-exon encoding domains at the
whole genome level remains to be determined. High-resolution
array CGH has also been implemented in cancer research. For
example, array-based methylated CpG island amplification
(BAMCA) was developed to screen aberrant methylated CpG-
rich sequences genome-wide in order to study the silencing of
tumor suppressor genes [21].
Array CGH has unequivocally established its reliability in
detecting copy-number changes, and several groups have now
implemented this technology in clinical evaluation of both
postnatal [22–25] and prenatal patient samples [26–31]. In
comparison with research arrays, the clinical arrays must be
carefully designed to precisely detect genomic imbalances for
which clinical interpretations can be rendered. Our group initially
developed and validated a BAC/PAC array in our clinical
cytogenetics laboratory for Chromosomal Microarray Analysis
(CMA V4) [24]. This version contained 366 FISH verified BAC/
PAC clones that span genomic regions implicated in over 43
known genomic disorders [32] as well as all 41 subtelomeric
regions. Subsequently, an expanded version of the array, CMA V5
that contains 853 FISH verified clones was implemented that
detects gains and losses due to genomic rearrangements associated
with over 70 disorders. Expansion of genome coverage in clinical
arrays is always accompanied by the detection of copy number
variation (CNVs) that might represent benign polymorphic
changes.
Here, we present clinical experience with two versions of CMA
arrays in the evaluation of 2513 clinical postnatal patient samples
studied in our clinical diagnostic laboratory between February
2004 and March 2006 (Table 1). We compare these two versions
with respect to detection rates for pathological chromosomal
abnormalities and for CNVs, the latter most often representing
benign variation. Our substantive dataset enables robust assess-
ment of the implementation of this technology in patient
management and as an aid to the establishment of a specific
etiologic diagnosis.
RESULTS
All clinically relevant abnormal CMA results including de novo
single clone changes [33] described in this section are listed in the
Supplementary Tables S1 and S2; case ID numbers V4-1,59
were performed on CMA V4 and ID numbers V5-1,154 were
conducted on CMA V5.
CMA Concordance with Abnormal Cytogenetics
Findings
The molecular based and targeted CMA approach detected the
majority (92.5%) of those genomic imbalances identified by
cytogenetic studies, including numerical changes, deletions and
duplications (N=43) and two marker chromosomes (case V4-27
and case V5-115) as well as two cases with .50% mosaicism
involving a ring chromosome 22 (case V4-50) or monosomy X
(case V4-52). CMA further identified the additional material of
unknown origin and delineated breakpoints on all derivative
chromosomes, thereby often having the added advantage of
refining genomic intervals involved in the imbalance (N=26) such
as in case V4-31, case V5-41 and case V5-35 (Table S1 and S2).
Moreover, on CMA V4, (case V4-33) a microduplication at
17p11.2-p12, that includes both the Smith-Magenis syndrome
(SMS) and Charcot-Marie Tooth disease type 1 A (CMT1A)
critical regions, was observed in one patient previously reported as
having an abnormal 47,XYY karyotype. The additional genomic
imbalance detected by CMA may explain the clinical findings
including growth retardation and dysmorphic features, which were
inconsistent with 47,XYY karyotype in this patient. Likewise, in
a patient (case V5-144) with autistic behavior, developmental
delay and dysmorphic features for whom cytogenetic studies
showed a 47,XXY karyotype, CMA V5 revealed a smaller gain in
the pericentromeric region of chromosome 7 including the
Williams-Beuren syndrome (WBS) critical region at 7q11.23,
which was confirmed by FISH analysis to be caused by a mosaic
small ring chromosome 7 in 33% of the cells.
As anticipated, neither CMA V4 nor V5 could detect the
apparently balanced translocations (N=12), inversions (N=21),
insertions (N=2), fra(X) expansions (N=2) or extremely low level
(,10%) mosaicism (N=3). CMA V4 also failed to identify one
marker chromosome, but this could be due to the limited array
coverage. However, CMA V5 identified gains of the DiGeorge
syndrome/Velocardiofacial syndrome (DGS/VCFS) genomic re-
gion not identified in two patients undergoing cytogenetic
evaluations, which described apparently balanced translocations.
One patient (case V5-109) with developmental delay and
Table 1. General comparison of CMA results correlated with routine cytogenetic results
..................................................................................................................................................
CMA V4 CMA V5
Total
cases
Abnormal
cases
Detection
rate (%)
Total
cases
Abnormal
cases
Detection
rate (%)
Total patients studied 775 59 7.6 1738 154 8.9
Patients with abnormal karyotype/FISH 44 28 63.6 73 45 65.7
Karyotype/FISH performed prior to CMA 26 12 43 26
Karyotype/FISH performed concurrently with CMA 18 16 30 19
Patients with normal karyotype/FISH 680 28 4.1 1192 70 5.9
Karyotype/FISH performed prior to CMA 462 24 855 56
Karyotype/FISH performed concurrently with CMA 218 4 337 14
Patients with karyotype/FISH not available 51 3 5.9 473 39 8.2
Karyotype/FISH performed prior to CMA 27 2 97 10
Karyotype/FISH performed concurrently with CMA 24 1 138 8
Karyotype/FISH not ordered 0 0 238 21
doi:10.1371/journal.pone.0000327.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Clinical Implementation of CMA
PLoS ONE | www.plosone.org 2 March 2007 | Issue 3 | e327ambiguous genitalia had a karyotype indicating 46,XX,t(2;9)-
(p25.3;p22.1) whereas the other patient (case V5-110) manifested
developmental delay and dysmorphic features and the identified
karyotype of a three-way translocation 46,XX,t(12;18;13)(q14;
q21.3;q14.2). Thus, although CMA does not detect balanced
translocations or inversions it may uncover other cryptic genomic
imbalances that are not detected by conventional cytogenetics in
patients with phenotypic abnormalities and apparently balanced
rearrangements. Interestingly, V5 also detected an apparent low
level mosaic trisomy 14 (case V5-143); although subsequently
validated by karyotype and FISH, both of these methods identified
only 2% of cells with trisomy 14 in PHA stimulated T-cells [34].
Clinically Relevant Genomic Imbalances Identified
by CMA in Cases with Normal Cytogenetics Findings
CMA identified genomic imbalances not detected by conventional
clinical cytogenetic analyses in a total of 5.2% of the patients; this
represents 4.1% (20 losses and 5 gains) and 5.9% (39 losses and 38
gains) rates using V4 or V5, respectively (Table 1). Each of these
abnormalities was confirmed independently by repeated GTG-
banding and/or FISH tests. The confirmatory method used was
dependent on the size of the genomic imbalance detected by
CMA. These findings indicate that increasing the genomic cover-
age on the V5 targeted array enabled higher resolution and a 44%
higher rate of detection of genomic imbalance compared to V4.
All the patients studied in this category are summarized in 5
groups based on the clinical indications provided at time of referral
in Table 2. In group I, which are the patients with DD/MR only,
the CMA clinically relevant detection rate was 3.9%; in group II,
which are patients whose clinical indication was a combination of
DD/MR and DF or MCA, CMA detected clinically relevant
imbalances in 5.6%. CMA was most clinically sensitive, with the
highest detection rate at 8.4%, in Group III, which are the patients
with dysmorphic features (DF), multiple congenital anomalies
(MCA), or the combination of both. Our targeted CMA detected
fewer (3.4%) genomic imbalances in the Group IV patients with
autistic behaviors; however, this group of patients will be further
analyzed using a higher density array. CMA sensitivity in group V
patients whose clinical indications represent ‘‘others’’ (e.g., seizure
disorders, learning disability, failure to thrive, etc.) was 5.3%.
There were three cases in the category reported to have normal
karyotype, normal locus specific FISH test at the DGS/VCFS
critical region and normal telomeric FISH test. CMA V4 identi-
fied a de novo gain in the Miller-Dieker lissencephaly syndrome
(MDLS) critical region in 17p13.3 for one patient (case V4-35); V5
revealed one duplication at the DGS/VCFS located in 22q11.2
(case V5-103), and a de novo gain at 4q22.3 (case V5-31) that was
detected by a single clone. CMA V5 also detected five cases with
mosaicism for aneuploidies ranging from 10–60% (cases V5-121,
V5-151,V5-154) that were not detected by routine cytogenetic
analysis. The somewhat surprising ability of CMA to identify
mosaicism not detected by karyotype analysis may be due to the
difference in samples used for each test, as only PHA-stimulated T-
cells are analyzed in routine chromosomal analysis whereas CMA
uses genomic DNA from whole blood containing multi-lineage
nucleated cells [34].
Clinically Relevant Genomic Imbalances Identified
by CMA in Cases without a Karyotype
For this group of patients, the sensitivity for detecting clinically
relevant genomic imbalances was 5.9% (3/51) on version 4 and
8.2% (39/473) on version 5, respectively (Table 1). All the geno-
mic imbalances detected by CMA were verified using the most
appropriate method, either GTG-banding or FISH. Using CMA
V4, there were two cases identified with microdeletions, one at
1p36.3 (case V4-3) and one at the DGS/VCFS locus (case V4-51).
Using CMA V5, 19 cases had interstitial microrearrangements (12
losses and 7 gains), and 14 cases were identified with subtelomeric
rearrangements. In retrospective high-resolution GTG-banding
analyses of these 42 abnormal cases, 24 of these genomic
imbalances were not detectable by routine cytogenetic analysis
(Table S1 and S2).
Notably, there was an increase in the overall detection rate of
genomic imbalances with CMA V5 (8.9%) relative to CMA V4
(7.6%) (Table 1), indicating that the increase in coverage of
genomic disorder regions in the array enables additional
imbalances to be identified in these screening tests even in the
absence of case selection on the basis of normal cytogenetic
studies.
Microdeletions and the Reciprocal
Microduplications
There were 90 cases in which losses or gains associated with
cryptic chromosomal microdeletions (51 cases) or the apparent
predicted microduplications (39 cases) were detected (Table 3).
Thirteen chromosomal regions associated with 11 known disorders
involving microdeletions and microduplications, including 1p36
monosomy, 1q21.1 (novel), 1q44 (novel), Wolf-Hirschhorn syn-
drome (WHS) (4p16.3), cri-du-chat syndrome (CDCS) (5p15.3),
WBS (7q11.23), WAGR (Wilm’s tumor, aniridia, genital/or
urinary tract abnormalities, mental retardation) (11p13), Prader-
Willi/Angelman syndromes (PWS/AS) (15q11.2), MDLS
(17p13.3), CMT1A/hereditary neuropathy with pressure palsies
(HNPP) (17p12), SMS (17p11.2), neurofibromatosis type 1 (NF1)
(17q11.2) and DGS/VCFS (22q11.2). For all 13 regions that were
observed to undergo genomic losses, we also found cases with
gains potentially representing reciprocal duplications; such events
were observed at unequal frequencies (Table 3). The most
commonly identified rearranged genomic regions include 1p36
(11 del/5 dup), 7q11.23 (6 del/3 dup), 15q11.2 (3 del/3 dup) and
22q11.2 (17 del/7 dup). Among these 90 cases, a subset of 70
patients (45 deletions and 25 duplications), had undergone
previous cytogenetics and subtelomeric and/or locus specific
FISH tests. Of these, 35 deletions (78%) and 23 duplications (92%)
were not detected by conventional cytogenetic methods. Chro-
mosomal regions at 1q21.1 (2 del/4 dup) and 1q44 (1 del/5 dup)
include microrearrangements which have not been extensively
Table 2. CMA results correlated with clinical indication in the
patients with normal cytogenetic tests
......................................................................
Group
Clinical
indication
Total NL
cyto
Total ABNL
CMA
CMA
detection rate
I DD/MR 620 24 3.9%
II DD/MR+/2DF or MCA 375 21 5.6%
III DF, MCA or both 299 25 8.4%
IV Autism 146 5 3.4%
V Others* 432 23 5.3%
Total 1872 98 5.2%
DD: developmental delay; MR: Mental retardation; DF: Dysmorphic feature;
MCA: Multiple congenital anomalies
*including seizure disorders, failure to thrive, short stature, speech delay,
learning disability, etc.
NL: normal; ABNL: abnormal
doi:10.1371/journal.pone.0000327.t002
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PLoS ONE | www.plosone.org 3 March 2007 | Issue 3 | e327reported in the literature. Genotype-phenotype correlation studies
are ongoing to determine whether imbalances in these two regions
represent novel genomic disorders [35]. Figure 1 illustrates
examples of three pairs of microdeletions and apparent reciprocal
duplication syndromes at 15q11.2q13, 17q11.2 and 22q11.2
detected by CMA V4 and V5.
Moreover, CMA V5 detected an additional eight cases with
Xq28 gains that include the MECP2 gene responsible for Rett
syndrome [36]. Both CMA V4 and V5 illustrated improved
potential over conventional cytogenetic analysis for identifying
genomic imbalances associated with known microdeletions and
evolving microduplication syndromes.
Copy Number Variations (CNVs)
Two different types of apparent copy number variations were
detected (Table 4). Multi-clone CNVs were classified as genomic
segmental CNVs involving multiple interrogating clones from
a single genetic locus whereas single clone CNVs represent
genomic changes detected by only a single clone. Multi-clone
CNVs, detected in 50 cases by CMA V4 and 69 cases on V5, were
observed multiple times with either gains (in the majority of cases)
or losses at five pericentromeric or subtelomeric regions including
2q13 (8/V4, 19/V5), 11q25 (14/V5), 15q11.2 (10/V4 and 14/
V5), Xp22.3 (6/V4 and 13/V5), Yq11.2 (AZFc) (26/V4 and 9/V5)
(Figure 2). Most of these changes were also found in the pheno-
typically normal parents, suggesting likely benign alterations;
however, the potential clinical relevance of these CNVs remains
unknown. We interpreted several multi-clone CNVs as likely
representing normal variants by comparison to the Database of
Genomic Variants [37] (http://www.sanger.ac.uk/PostGe-
nomics/decipher).
There were 34 clones on version 4 and 109 clones on version 5
that were noted to reveal single clone gains or losses (Figure 2).
The results for each single clone CNV were independently
confirmed by FISH. A total of 98 CNVs (27 on V4 and 71 on V5)
were inherited from normal parents as determined by either
parental FISH or CMA testing and thus reported as familial
variants. The remaining 45 changes (seven on V4 and 38 on V5)
were queried on the public normal variation database (Toronto
database http://projects.tcag.ca/variation) and the database on
array CGH published by Iafrate et al [38], and none of these were
reported as known normal variants. Of the 45 single clone CNVs,
there were 11 (two on V4 and nine on V5) that revealed de novo
(Figure 2) rearrangements in comparison to parental samples and
thus, these are considered potentially causative for a phenotype
[33]. It should be noted that paternity testing was not performed
for these cases. For example, a single clone deletion (RP5-888M10)
at 1p36.1 on CMA V4 was seen in two patients (cases V4-1,2)
whose clinical phenotypic appears distinct from the 1p36.3
deletion syndrome and repeated CMA of one patient on V5,
with expanded coverage to 1p36.1 region, showed a more than
10 Mb deletion proximal to the typical 1p36.3 syndrome region.
Another single clone deletion (RP11-12L9) on chromosome 7 that
encodes the FOXP2 gene located at 7q31.1 was detected in case
V5-48. Parental FISH studies with this clone further indicated that
the second copy of this clone was inserted into one chromosome
10 in the mother, uncovering a complex rearrangement in the
child. This rearrangement was interpreted to be the cause of
patient’s phenotype of speech and language impairment [39].
Finally, 34 clones revealing gains or losses were considered as
CNVs with unknown clinical significance and await familial
studies for interpretation.
DISCUSSION
CMA Increases Detection of Genomic Imbalances
Array CGH offers the potential for high throughput and high-
resolution genome analysis and is a less labor intensive approach
than other molecular cytogenetic analyses. In this study, we
illustrate the value of array CGH in a large collection of clinical
data (2513 cases). The targeted array enabled the detection of
genomic imbalances, especially in the patients with previous or
concurrent normal cytogenetic tests that were referred for DF,
MCA or both (Table 2). As the targeted genomic coverage was
increased, 17 additional abnormal cases were detected on the V5
array, including six cases associated with the newly assayed
genomic regions, nine cases involving newly added pericentro-
meric regions and two cases with gains/losses of subtelomeric
Table 3. Microdeletions and the potential reciprocal duplications
..................................................................................................................................................
Chromosome
region
Deletion
Syndrome
Duplication
Syndrome
V4 Clone
coverage
V5 Clone
coverage V4 del/dup
V5
del/dup
Total
del/dup
1p36.3 1p36 dup 1p36 4 24 7/1 4/4 11/5
1q21.1 1q21.1* dup 1q21.1 0 3 0/0 2/4 2/4
1q44 1q44* dup 1q44 8 12 1/2 0/3 1/5
4p16.3 WHS dup 4p16.3 8 8 0/1 4/0 4/1
5p15.3 CDCS dup 5p15.3 3 6 0/0 2/4 2/4
7q11.23 WBS dup 7q11.2 8 11 3/0 3/3 6/3
11p13 WAGR dup 11p13 5 9 0/0 1/1 1/1
15q11.2 PWS/AS dup 15q11.2q12 7 7 0/1 3/2 3/3
17p13.3 MDLS dup 17p13.3 4 4 0/2 0/0 0/2
17p12 HNPP CMT1A 3 3 0/1 1/1 1/2
17p11.2 SMS Potocki-Lupski dup 17p11.2 4 4 0/1 1/0 1/1
17q11.2 NF1 dup 17q11.2 4 3 1/1 1/0 2/1
22q11.2 DGS/VCFS dup 22q11.2 5 5 8/0 9/7 17/7
Total 90 20/10 31/29 51/39
*Chromosomal regions involved with microdeletions or microduplications that have not been reported previously.
doi:10.1371/journal.pone.0000327.t003
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PLoS ONE | www.plosone.org 4 March 2007 | Issue 3 | e327clones (data not shown), thus resulting in an enhanced overall
detection rate. This greater genomic coverage on V5 also increased
the rate at which single clone CNVs were identified. The
heightened overall detection rate using V5 may also be due to
factors such as technical improvements, improved experience in
the data interpretation, and better selection of the clone coverage.
For example, selected reduction of clones revealing known multi-
clone CNVs led to a very significant reduction (57.5%) in the
identification of these CNVs in patient samples using targeted V5
versus V4 arrays (Table 4).
Submicroscopic or subtelomeric chromosomal rearrangements
have been found in about 6% of patients with otherwise
unexplained mental retardation or multiple congenital anomalies
[8,40]. Array CGH has the capability of identifying such
subtelomeric cryptic imbalances [41,42]. In addition to the
previously identified interstitial and subtelomeric imbalances, our
CMA detected also all genomic gains and losses in patients with
both normal karyotypes and FISH results. Because subtelomeric
FISH analyses routinely include only one clone for each
chromosome end, smaller and/or interstitial rearrangements can
be missed. Similarly, microduplications are often missed by
metaphase FISH because the duplicated signals are in close
proximity to each other and cannot be distinguished on metaphase
chromosomes; interphase FISH is required to resolve the dupli-
cated signals and it is important to differentiate duplication from
Figure 1. Example of reciprocal deletion/duplication CMA ratio plots with FISH validation. A Three sets of ratio plots showing examples of reciprocal
microdeletion and microduplication at PWS/AS (on V5), NF1 (on V4) and DGS/VSFS (on V5) critical regions on chromosomes 15q11.2, 17q11.2 and
22q11.2, respectively. The vertical lines represent the BAC clones interrogating targeted regions of the genome, aligned according to their
chromosomal position with the signal intensity ratios observed from the combined dye-swap experiments. Gains (G) are to the right and losses (L) to
the left. Red circles highlight the signal ratios revealing genomic losses whereas the blue circles indicate copy number gains consistent with genomic
deletions and reciprocal duplications, respectively. B FISH validation results. Control probes were labeled with a green chromophore and clones
detecting deletions (in metaphase) or duplications (in interphase) were labeled in red for PWS/AS del/dup, NF1 del/dup and DG/VCFS del/dup.
doi:10.1371/journal.pone.0000327.g001
Table 4. Copy Number Variations (CNVs)
......................................................................
V4 V5 V4 detected V5 detected
Multi-clone CNVs 50 69 6.5% 4%
Single clone CNVs 34 109 4.4% 6.3%
Familial variant 27 71 3.5% 4.1%
De novo 2 9 0.3% 0.5%
Unknown significance 5 29 0.6% 1.7%
doi:10.1371/journal.pone.0000327.t004
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PLoS ONE | www.plosone.org 5 March 2007 | Issue 3 | e327Figure 2. Ideogram of Copy Number Variations (CNVs). Big arrows indicate CNVs Type 1 (N=119), except AZFc on the Y chromosome (N=35). *
represents V4 and for V5 for CNVs Type 2 (N=143). A total of 262 copy number variations (CNVs) were identified by CMA. Of these, 217 were
interpreted as familial variants (green) and 11 were determined to be de novo (red); 34 CNVs that await parental studies are depicted with unknown
clinical significance (black). Positions showing losses are on the left side of the chromosome whereas gains are on the right side.
doi:10.1371/journal.pone.0000327.g002
Clinical Implementation of CMA
PLoS ONE | www.plosone.org 6 March 2007 | Issue 3 | e327replication in a G2 phase nucleus [43]. Using CMA we identified
four cases with gains at telomeric regions that were missed in
previous subtelomeric FISH analyses. One of these patients had
dysmorphic features, developmental delay and an autistic-like
behavioral phenotype. Normal results were reported for routine
G-banding, subtelomeric and probe specific FISH (at DGS/VCFS
region) and fragile6testing. CMA identified a three-clone de novo
gain due to duplication at the MDLS locus on 17p13.3 and these
findings were confirmed by FISH. This latter case further
illustrates the power of CMA as a rapid diagnostic technology
capable of simultaneously interrogating multiple regions of the
genome in a single test.
Array CGH also has an advantage in detecting microdeletions
and the reciprocal microduplications at both interstitial and
subtelomeric regions. A common mechanism for recurrent
interstitial microrearrangements has been determined to result
from nonallelic homologous recombination (NAHR) (intrachro-
mosomal, interchromsomal or intrachromatid unequal crossing-
over) between low-copy repeats (LCRs) [44,45]. Such NAHR may
produce two reciprocal products; a tandem (or direct) duplication
and a deletion. The de novo events are predicted to occur at similar
frequencies unless there is rearrangement specific selection or
ascertainment bias, and, thus, it might be anticipated that both
events would be seen in the population with equal frequency unless
prenatal lethality, a milder phenotype with less likelihood to be
studied or reduced penetrance occurs for the duplication or the
deletion. Several reciprocal recombination disorders were de-
lineated under this hypothesis, including duplications causing
CMT1A and deletions causing HNPP [43,46] at 17p12 and SMS
deletion and Potocki-Lupski dup(17)(p11.2p11.2) syndrome [47]
as well as rearrangements in 7q11.23, 15q11.2 and 22q11.2 [48].
In this study, CMA identified 90 cases that involved 13 differ-
ent reciprocal microduplication-microdeletion rearrangements
(Table 3). The most common cytogenetic regions involved include
1p36.3, 15q11-q13, and 22q11.2. Two of 13 regions were novel
and patients with these reciprocal rearrangements are now being
analyzed in depth.
Balanced Translocations and ArrayCGH
CMA is limited to identifying genomic imbalances. Thus,
balanced chromosomal translocations, inversions and insertions
are not detected. Balanced translocations, in theory, should be
benign unless the breakpoint disrupts a dosage sensitive gene or
conveys a position effect. This is particularly important to consider
in patients who have an abnormal phenotype, but the karyotype
appears to represent a de novo balanced translocation. Several
groups have focused on array CGH studies of patients with
abnormal phenotypes and apparently balanced (primarily de novo)
translocations based on routine cytogenetic analysis. Ciccone [49]
et al reported that three out of four of such patients with appar-
ently balanced translocations were actually unbalanced, and had
complex rearrangements. They proposed that the array detected
imbalances accounting for the mental retardation and other
phenotypic abnormalities observed. Using a 1 Mb genome array,
a cryptic 0.15–1.5 Mb deletion was detected at one of eight
breakpoints of an apparently balanced three-way chromosomal
translocation in a patient with behavior problems [50]. In another
study, involving ten patients with de novo balanced translocations
and abnormal phenotypes, a 1 Mb array detected genomic
imbalances in six patients [51]. Thus, array CGH has the
potential to detect imbalances in a considerable percentage of
patients who have apparently balanced translocations based on
routine cytogenetics, particularly in patients with abnormal
phenotypes. For this application, tiling path rather than focused
arrays are more appropriate.
In patients with a previous cytogenetic study, CMA did not
detect additional gains or losses in 12 patients with apparently
balanced translocations (4 de novo, 2 familial and 6 unknown).
There are three possible explanations. First, there were neither
genomic regulatory elements nor genes disrupted at breakpoint
regions or if they were, the genes were not dosage sensitive.
Second, the negative CMA results of balanced translocations could
reflect the limitation of our current array with respect to clone
coverage at these chromosomal breakpoints. Third, the un-
balanced rearrangements at breakpoints were too small to detect
using BAC/PAC array technology. Although we did not identify
any genomic imbalances at the breakpoint regions in patients who
had previously reported balanced translocations, we did discover
microduplications at 22q11.2 in two patients that might account
for their abnormal phenotypes. A recently developed array
painting technology [52,53] could potentially aid in detection
and further resolution of complex chromosomal translocations that
appear to be balanced by providing higher resolution genome and
accurate breakpoint analyses. Likewise, extremely high density
microarrays, such as oligonucleotide arrays [54] could be used to
characterize apparently balanced translocations, inversions, geno-
mic imprinting and with the inclusion of oligonucleotides
interrogating single nucleotide polymorphisms (SNPs) also detect
uniparental disomy (UPD) [55].
Increasing Clone Coverage with Targeted Arrays
Detected More Genomic Imbalances but also
Increased the Detection of Benign Variants
Several recent studies have emphasized the extent of copy-number
variations (CNVs) in the human genome. Iafrate et al. used
a human 1 Mb BAC array with ,3000 clones on a panel of 55
unrelated individuals and found more than 200 clones detecting
CNVs, 24 of which were present in .10% of the individuals; there
was an average of 12.4 CNVs per individual [38]. Sebat et al.
using oligonucleotide arrays to study only 20 individuals described
221 copy number differences representing 76 unique CNVs; they
found an average of 11 CNVs per individual and the average
length of the CNVs was 465 kb [56]. Both studies found 60–70
entire genes within CNVs. One study using oligonucleotide arrays
found a median of 30 (range 19–34) CNVs per index case with
mental retardation [57]. More recently, Goidts and colleagues
found copy number differences by inter-species array CGH
analysis, and a total of 322 sites of large-scale interspecies
differences which were identified by comparing human genomes
with those of other primates. They suggested that human-specific
duplications (i.e. 2q13) may predispose to chromosomal rearran-
gement [58]. By using full coverage BAC array CGH, Wilson et al.
discovered that human DNA copy-number is often increased
relative to chimpanzee and gorilla. Several chromosomal regions,
such as 1p36.13, 1q21.1, 2q13, 4p16.3, 7q11.23, 9p12, 15q11.2,
were established with higher copy number changes in human [59].
Most of these regions overlap with those involved with known
human microdeletions and microduplication syndromes [45,60].
In the current study, the enhanced resolution of CMA V5
improved the overall detection rate of chromosomal abnormalities
significantly (Table 5), but also identified more single clone CNVs;
however, the multi-clone CNV detection rate was reduced
(Table 4) due to improved array design. We identified two major
types of CNVs according to likely phenotypic effects. One group
involving five chromosomal regions 2q13, 11q25, 15q11.2,
Xp22.3 and Yq12 (AZFc) were hypothesized as benign variations
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interpretation is consistent with the CNV database (Toronto
database http://projects.tcag.ca/variation). However,acontinuing
genotype-phenotype correlation study is required to better
understand any potential relevance of these CNVs to a particular
phenotype, particularly when inherited in combination as distinct
alleles from each parent [60,61]. CNVs involving at least 34 BAC/
PAC clones remain of uncertain clinical significance; the majority
of these CNVs involve gain (N=26) detected by clones located at
the telomeric/subtelomeric and pericentromeric regions. It is
uncertain at present what proportion of these variations are benign
versus pathological, and whether they occur with increased
frequency near telomeres [62]. De novo gains or losses are much
more likely to be pathological [33] compared to those inherited
from a normal parent, and one study using SNP arrays interpreted
the clinical significance almost entirely according to whether
variation was inherited or de novo [57]. However, variants could
occasionally have variable penetrance with the same allele causing
a phenotype in the child but not the parent. Studies of variants
within extended families may be required to determine if certain
CNVs have variable penetrance for phenotypic effects. Additional
investigations of family members, computational analysis in
combination with published databases and systematic analysis of
genomic polymorphisms will provide further insight into the
plasticity of the human genome, therefore helping to determine if
these are normal variations, disease susceptibility variants, or may
cause disease in association with other alleles [60].
Does Genomic Sequence Determine Chromosome
Folding?
There were 14 cases on V4 and 46 cases on V5 reported with
a normal karyotype and/or FISH performed either prior to CMA
or concurrently with CMA. After CMA revealed the abnormalities
of deletions and/or duplications ranging from 0.5 Mb to over than
10 Mb, a high resolution (at average 650 banding) retrospective
karyotype was applied (Tables S1 and S2). In general, on V4, six
cases (,3 Mb) of 14 showed no evidence of cytogenetic
abnormalities while the remaining eight cases (.5 Mb) were
found to have abnormal chromosomes. On V5, 33 cases showed
a negative retrospective karyotype whereas the remaining 13 cases
revealed visible chromosomal abnormalities. The estimated
smallest rearrangement visible by cytogenetic banding was
a 2.7 Mb loss (in case V5-28), and the estimated largest size
aberration missed by traditional cytogenetics was a 7.2 Mb
duplication (in case V5-59). However, the size of deletion or
duplication estimated by CMA might not truly reflect the exact
size of the rearrangement due to the limitation of the current
targeted array with lack of clone coverage at some of the
chromosome regions. Our data from retrospective karyotyping
raises an important question: why are some changes of ,3M b
cytogenetically visible whereas ,7 Mb changes may not be seen
cytogenetically? Does this relate to the mechanism of packaging
of the genome into chromosomes and genomic sequences
required for chromosome folding revealed by G-banding?
Potential explanations for discrepancies between genome size
and cytogenetic detection include: 1) altered trypsin access to
the folded chromosomes, 2) chromosomes failing to stretch
during the preparations in the region of genomic imbalances or,
3) the distribution of chromosome condensation and the
hierarchical folding [63,64]. Shopland and colleagues found that
the gene distribution pattern in primary sequence contributes to
chromosome folding and organization in mice [65], and thus
genomic sequence could be involved in the determination of
chromosome folding. Systematic evaluation of genomic sequences
from regions discrepant for rearrangement size visualized by
arrays versus G-banding may reveal further insight into chromo-
some folding.
Future Perspectives
In conclusion, this study demonstrates that CMA is a valid
methodology for clinical testing. CMA is equivalent to performing
hundreds of subtelomeric and locus specific FISH tests simulta-
neously, and it also reliably detects duplications that are not
usually seen by metaphase FISH. Thus, CMA offers an efficient
and high-throughput alternative for detecting and characterizing
genomic imbalances. An informed approach in targeted array
CGH design can improve detection of clinically relevant genomic
imbalances and reduce detection of common, apparently benign
CNVs as shown for our V5.
We have designed a higher density array CMA V6 which will
cover more disease specific regions, enhance the coverage of each
chromosomal band and further incorporate interrogation of
genomic regions with architectural features causing susceptibility
to rearrangements [66]. By doing so, we should increase the
detection of rearrangements associated with novel genomic
disorders, and perhaps also increase the detection rate among
patients with apparently de novo balanced translocations but having
unexplained phenotypes as we showed for the V5 to V4 transition.
Much higher density arrays, such as the whole genome tiling
path arrays [15] or oligonucleotide arrays [54,66] are likely to be
implemented in clinical diagnosis in the near future, but clinical
interpretation and counseling will be challenging because of
CNVs. A targeted oligoarray will eventually have the potential
feasibility in design that enables detection of all clinically relevant
genomic imbalances and, in combination with CNV databases,
interpretation of benign polymorphic CNVs. Such high resolu-
tion genome analysis is a complementary alternative to DNA
sequence based genetic testing and other biochemical and
cytological evaluations for exploring the genetic etiologies of
disease.
MATERIAL AND METHODS
CMA was previously validated on DNA samples from human
subjects under an IRB approved protocol. It was introduced in
February 2004 as a clinical test coupled with FISH confirmation of
potential imbalances ascertained after screening by CMA [24]
(http://www.bcm.edu/cma/).
Table 5. Comparison of targeted array CGH clinical
implementation studies
......................................................................
V4 V5
Shaffer
et al (2006)
Genomic clone coverage 366 853 831
Genomic region coverage 84 154 126
Total patients studied 749 1695 1500
aCGH abnormality 128 (17.1%) 274 (16.2%) 134 (8.9%)
Clinical relevant genomic imbalances 46 (6.1%) 125 (7.4%) 84 (5.6%)
Unknown clinical significance 5 (0.6%) 9 (0.5%) 14 (0.9%)
CNVs 77 (9.9%) 140 (8.1%) 36 (2.4%)
Cases with known abnormal cytogenetic results on both V4 and V5 were
excluded
doi:10.1371/journal.pone.0000327.t005
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Peripheral blood samples from a total of 2513 patients were
submitted to the BCM Clinical Cytogenetics Laboratory between
February 2004 and March 2006 with a request for CMA. Most
cases had either previous or concurrent conventional cytogenetic
analysis by GTG-banding or FISH (Table 1). In general, patients
referred for CMA analysis had variable clinical phenotypes, most
often including: developmental delay and/or mental retardation
(DD/MR), dysmorphic features (DF), multiple congenital anom-
alies (MCA), seizure disorders and autistic or other behavioral
abnormalities. Clinical indications at the time of referral are
summarized in 5 groups (Table 6). We also noted that for the
patients in Group III, the majority (,75%) of the patients were
under age 2 at the time being tested, therefore, they were not fully
evaluated for DD/MR.
Overall, 775 samples which were analyzed using CMA V4 and
1738 samples were studied using CMA V5 (Table 1).
There were a total of 117 patients (44 on V4 and 73 on V5) for
whom cytogenetic studies were abnormal by GTG-banding analy-
sis (N=113) and FISH tests (N=4). In 69 cases the cytogenetic
studies were done previously whereas in 48 cases the cytogenetic
and CMA studies were performed concurrently (Table 1). Un-
balanced chromosomal abnormalities (N=80) detected included:
18 numeric changes of whole chromosomes; 22 chromosomal
deletions and five duplications; nine with additional chromosomal
material of unknown origin; 17 with derivative chromosomes and
three with marker chromosomes. There are six cases with
mosaicism that included two ring chromosomes (90% and 6%
mosaicism) and four numeric abnormalities (84% mosaic mono-
somy chromosome X, 8% mosaic trisomy chromosome X, 2%
mosaic trisomy chromosome 14 and 1% mosaic trisomy
chromosome 9). Apparently balanced chromosomal abnormalities
subjected to further analysis (N=37) were found to include 12
balanced translocations, 21 inversions, two insertions, and two
fra(X) expansions (detected by molecular methods).
CMA studies were conducted on 1872 patients with a normal
karyotype by GTG-banding, a subset of whom also had normal
subtelomeric and/or locus specific FISH. CMA V4, which con-
tained 366 arranged BAC/PAC clones, was used in 680 cases, in
which 462 cases had cytogenetic tests prior to CMA and 218 cases
were concurrent with CMA; CMA V5 with 853 interrogating
clones was implemented in 1192 cases, there were 855 cases that
had previous cytogenetic tests, whereas 337 cases whose cyto-
genetic tests were performed with CMA concurrently (Table 1).
There were 524 patients studied, 51 performed using CMA V4
and 473 using CMA V5, for whom no information was available
regarding a previous or concurrent karyotype and/or FISH
analysis. A subset of the cases on V5 was ordered for CMA only.
Array CGH
The CMA array V4 consisted of 366 BAC/PAC clones and V5
consisted of 853 clones (Table S3). Both were designed to contain 3
to 10 BAC/PAC clones per genomic disorder specific locus and
subtelomeric regions. The version CMA V5 covered over 70 genetic
disorders, all the clinically relevant subtelomeric regions (expanded
from 5 Mb to 10 Mb per region), pericentric clones for detecting
marker chromosomes, and clones that broadly span chromosomes
13, 18, 21, X, and Y for detection of these most common
aneuploidies and their mosaicism. Additional ‘‘backbone’’ interro-
gating clones along each chromosome were added to aid in the
detection of chromosome imbalance outside of targeted regions.
Array technology for printing and hybridization for this study
was described before [24] except for the additional use of a Tecan
automated hybridization unit for some samples for CMA version 5
with slight modification of the manufacturer’s recommended
protocol (Tecan HS 4800 hybridization station, Tecan Group Ltd,
Switzerland).
Array Scan and Data Analysis
Arrays were scanned into 16-bit tiff image files using an Axon two-
color microarray scanner (Model 4000B) and quantified using
GenePix Pro 6.0 (Molecular Devices Corp, Union City, CA) or
Bluefuse (BlueGnome, Cambridge, UK).
Data analysis was performed by a web-based software platform
utilizing an analysis scheme in the R open source statistical
computing language. The system generates results in the form of
raw, normalized and integrated data for all clones analyzed from
a single patient sample as described previously [24]. In addition to
computing the log2 Test/Reference intensity ratio value, a single
clone T-statistic and permutation based p-value is also computed
thereby providing further criterion to determine whether a clone
deviates significantly from the mean. In general, abnormal results
can be classified as gain or loss. A gain is defined when the
combined score of a clone is greater than 0.2 for the log Test/
Reference ratios and T-statistics permutation based p-value is
,0.05 while a loss is defined by the combined score being less than
20.2 with T-statistics permutation based p-value ,0.05. If a gain
or loss of a single or multiple clones are indicated, confirmatory
FISH analyses are performed. There are several categories of
results that were reported: (1) no abnormalities detected by this
version of the microarray; (2) clinically significant abnormalities
detected, which were known to be associated with a genetic
condition and confirmed by either FISH analysis and/or
chromosome analysis and/or partial karyotype; (3) copy number
gain or loss of uncertain clinical significance. This latter category
might involve either single clone or multiple clone copy number
changes that were either (3a) confirmed by FISH analysis or (3b)
NOT confirmed by FISH analysis. Subsequent parental FISH
and/or CMA studies were requested to determine if the copy
number changes represent familial variants or a de novo event and
potentially a clinically significant finding.
FISH Validation
Metaphase preparations from patient peripheral lymphocytes
followed a standard protocol [46]. BAC or PAC clone DNA
probes were labeled using Biotin-14-dUTP, Digoxigenin dUTP,
Spectrum Orange/Green according to published protocols. FISH
analysis was performed using the standard clinical cytogenetics
laboratory protocol.
Table 6. Summary of patient clinical indications at the time of
referral
......................................................................
Group Clinical indication V4 V5 Total cases
I DD/MR 272 566 838
II DD/MR+/-DF or MCA 140 330 470
III DF, MCA or both 119 255 374
IV Autism 55 159 214
V Others* 189 428 617
Total 775 1738 2513
DD: developmental delay; MR: Mental retardation; DF: Dysmorphic feature;
MCA: Multiple congenital anomalies
*including Seizure disorders, failure to thrive, short stature, speech delay,
learning disabilities, etc.
doi:10.1371/journal.pone.0000327.t006
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Table S1 Clinically Relevant Abnormal CMA Cases for Version
4
Found at: doi:10.1371/journal.pone.0000327.s001 (0.14 MB
DOC)
Table S2 Clinically Relevant Abnormal CMA Cases for Version
5
Found at: doi:10.1371/journal.pone.0000327.s002 (0.34 MB
DOC)
Table S3 Genomic Disorder loci coverage on CMA Version 4
Found at: doi:10.1371/journal.pone.0000327.s003 (0.32 MB
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